Biopharmaceutical company developing immunotherapies for cancer and other difficult-to-treat diseases.
Celldex Therapeutics, Inc. is a pioneering biopharmaceutical firm dedicated to advancing therapeutic monoclonal and bispecific antibodies for a spectrum of diseases. Established in 1983 and based in Hampton, New Jersey, Celldex Therapeutics focuses on innovative antibody-based therapies targeting inflammatory disorders and various cancers.
The company's robust pipeline includes promising candidates such as CDX-0159, a Phase I monoclonal antibody designed to bind and inhibit the receptor tyrosine kinase KIT. Another key program is CDX-1140, a human agonist monoclonal antibody that targets CD40, crucial for activating immune responses in dendritic cells, macrophages, B cells, and cancer cells alike. Additionally, CDX-527, a bispecific antibody, uniquely combines Celldex's proprietary anti-PD-L1 and CD27 human antibodies to stimulate anti-tumor T cell responses through CD27 costimulation while blocking the PD-L1/PD-1 pathway.
Celldex Therapeutics leverages strategic collaborations to fuel its innovative endeavors. Partnerships include research agreements with the University of Southampton, focused on developing human antibodies for CD27, and collaborations with Amgen Inc., granting exclusive rights to CDX-301 and CD40 ligand. Furthermore, the company maintains a significant collaboration with Yale University, underscoring its commitment to advancing cutting-edge therapeutic solutions.
With a rich history of innovation spanning several decades, Celldex Therapeutics continues to push the boundaries of antibody-based therapies. Through its dedicated research efforts and strategic partnerships, the company strives to address critical unmet medical needs and improve outcomes for patients worldwide.